Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and device for developing disease marker by using immunoglobulin-associated proteome

An immunoglobulin and proteome technology, applied in the field of developing disease markers, can solve the problems of few antigen identities and elusive immunoglobulin homology characteristics, and achieve the effect of reducing complexity

Pending Publication Date: 2022-03-01
香港城市大学深圳研究院
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, little is known about the identity of antigens beyond the atherosclerotic epitopes recognized by immunoglobulins
Furthermore, the question of whether and how the cognate signature of immunoglobulins evolves during adverse cardiovascular events remains elusive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and device for developing disease marker by using immunoglobulin-associated proteome
  • Method and device for developing disease marker by using immunoglobulin-associated proteome
  • Method and device for developing disease marker by using immunoglobulin-associated proteome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1, Quantitative analysis of immunoglobulin-associated proteome (IgAP)

[0067] Serum samples from 38 AMI patients, 20 stable CAD patients, and 37 individuals diagnosed with non-CAD / AMI (NCA) disease constituted a discovery cohort. Table 1 summarizes the clinical characteristics of patients with CAD and AMI.

[0068] Table 1. Demographic characteristics of the MS dataset

[0069]

[0070]

[0071] *± indicates standard error (SE). / indicates a data gap.

[0072] To study the immunoglobulin-associated proteome (IgAP), this example employs an IgAP assay that integrates purification of immunoglobulin complexes with label-free quantitative LC-MS / MS, as figure 1 As shown, the method includes:

[0073] According to the operation described in the aforementioned "1.3 IgAP isolation", the immunoglobulin-associated proteome with protein G agarose beads was isolated and purified from 20 μL serum of each individual using Protein G magnetic beads;

[0074] Accordi...

Embodiment 2

[0080] Embodiment 2, distinguish the CAD of AMI patient by IgAP

[0081] The present invention assessed whether IgAP profiles could differentiate AMI, CAD and NCA individuals using unsupervised hierarchical cluster analysis. As a result, 95 patient samples were classified into four main classes, which were named classes I to IV ( Figure 5 ). CAD individuals clustered well in group IV and were completely separated from AMI cases, which were distributed in groups II (21 cases) and III (16 cases), respectively. The complete separation of the CAD group from the AMI patients indicated a large difference between the IgAP profiles of CAD and AMI patients. As for the NCA samples, while cluster I contained only 18 NCA samples, clusters II, III, and IV contained 10, 5, and 4 NCA samples, respectively ( Figure 5 ). NCA patients came to the clinic for different reasons, so their unique clustering may be due to indeterminate clinical features independent of CAD / AMI.

Embodiment 3

[0082] Example 3, Differential enrichment of IgAP protein in patient population

[0083] Differential enrichment of IgAP protein between patient groups Complete isolation of CAD from AMI samples suggests that the presence of IgAP protein can differentiate atherosclerotic patients with and without myocardial infarction. Therefore, the present invention performed a pairwise comparison between IgAP proteins. Three patient groups. Comparing all AMI patients with CAD patients, 17 IgAP proteins were found to be significantly elevated in AMI patients ( Figure 6A-6B ). Gene Ontology (GO) analysis of these AMI-elevated IgAP identified complement and coagulation cascade pathways (FDR = 1.24 × 10 -6 ), where different complements (C1s and C1r) and coagulation factors (F10 and F5) represent proteins ( Figure 6A-6B ). Several variable regions of immunoglobulins (IGKV6D-21, IGHV1-69, IGKV1-12, IGHV1-46) were also elevated in IgAP of AMI patients. This result suggests that immunoglob...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method and a device for developing a disease marker by using an immunoglobulin-associated proteome. The invention provides a method for screening a disease marker. The method comprises a process of identifying the disease marker by using an immunoglobulin associated proteome. The method specifically comprises the following steps: separating immune globulin and binding protein in a sample by adopting a G protein cross-linked agarose bead technology; the separated protein is eluted from the magnetic beads; then carrying out trypsin digestion and desalination on the eluted protein; the desalted peptide sample is subjected to LC-MS / MS analysis by a label-free quantitative workflow. Hundreds of immunoglobulin binding proteins are quantitatively evaluated from a serum sample, a series of IgAP proteins are detected, and individuals in different health states can be classified.

Description

technical field [0001] The present invention relates to a technology for developing disease markers, in particular, a method and device for developing disease markers, especially cardiovascular disease markers, using immunoglobulin-associated proteomes. Background technique [0002] Atherosclerosis underlies the pathological development of coronary artery disease (CAD), the most common and life-threatening cardiovascular disease. Immune activity and chronic inflammation play a key role in the development of atherosclerosis, CAD, and susceptibility to undesirable tachycardia disorders such as acute myocardial infarction. At the cellular level, atherosclerotic lesions are characterized by the deposition of low-density lipoprotein (LDL), leading to a series of inflammatory responses as well as innate immune cells (such as monocytes / macrophages) and adaptive immune cells (such as T and B cells) respond continuously. Activated T cells are known to mediate adaptive immunity and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N30/02G01N30/34
CPCG01N33/6893G01N33/6854G01N30/02G01N30/34G01N2800/323G01N2800/324
Inventor 张亮王鑫谭苗苗
Owner 香港城市大学深圳研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com